Additionally, the Company has updated its pipeline chart, as shown below:
|
* |
The Companys clinical trial in China of CBP-201 in patients with AD is included as the Company intends to
submit a New Drug Application in China based on the results of this trial, pending pre-NDA discussions with the Chinese Center for Drug Evaluation of the National Medical Products Administration. |
|
** |
The CD Phase 2 trial ended early due to COVID-19-related enrolment challenges. |
Figure 1. Connect Biopharmas pipeline
This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 and S-8 (Registration Nos. 333-264340, 333-254524, and
333-266006, respectively) of the Company and to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished. The
information set forth in the attached exhibit shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, whether made before or after the date hereof,
except as expressly provided by specific reference in such a filing.
Forward-Looking Statements
The Company cautions that statements included in this report that are not a description of historical facts are forward-looking statements. Words such as
may, could, will, would, should, expect, plan, anticipate, believe, estimate, intend, predict,
seek, contemplate, look forward, potential, continue or project or the negative of these terms or other comparable terminology are intended to identify forward-looking
statements. These statements include the Companys plans to advance the development of its product candidates, the timing of achieving any development or regulatory milestones, and the potential of such product candidates, including to achieve
any benefit or profile or any product approval. The inclusion of forward-looking statements shall not be regarded as a representation by Connect Biopharma that any of its plans will be achieved. Actual results may differ from those set forth in this
report due to the risks and uncertainties inherent in the Connect Biopharma business and other risks described in the Companys filings with the SEC, including the Companys Annual Report on Form
20-F filed with the SEC on March 31, 2022, and its other reports. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the
Company undertakes no obligation to revise or update this report to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included in Connect Biopharmas filings with the SEC which are
available from the SECs website (www.sec.gov) and on Connect Biopharmas website (www.connectbiopharm.com) under the heading Investors. All forward-looking statements are qualified in their entirety by this cautionary
statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.